{
  "treatment_regimens": [
    "pembrolizumab plus platinum-based chemotherapy"
  ],
  "countries": [
    "United Kingdom",
    "Switzerland"
  ],
  "populations": [
    {
      "stage, histology": "IIIB/IVA, Adenocarcinoma",
      "pdl1_status": "Negative",
      "n": 164
    },
    {
      "stage, histology": "IVB, Adenocarcinoma",
      "pdl1_status": "Negative",
      "n": 113
    },
    {
      "stage, histology": "IIIB/IVA, Squamous",
      "pdl1_status": "Negative",
      "n": 51
    },
    {
      "stage, histology": "IVB, Squamous",
      "pdl1_status": "Negative",
      "n": 0
    },
    {
      "stage, histology": "IIIB/IVA, Other",
      "pdl1_status": "Negative",
      "n": 11
    },
    {
      "stage, histology": "IVB, Other",
      "pdl1_status": "Negative",
      "n": 0
    }
  ],
  "results": {
    "pembrolizumab plus platinum-based chemotherapy": {
      "median_os": "12.7 months",
      "median_rw_pfs": "8.0 months",
      "os_12_month": "52.2%",
      "group_difference": "Patients with high NLR (\u22654) had significantly shorter OS (median 11.8 vs 14.9 months, p=0.02) and PFS (median 6.6 vs 9.0 months, p=0.018) than those with low values."
    }
  },
  "study_name": "Study from Banna 2022.pdf",
  "file_name": "Banna 2022.pdf"
}